denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Sanofi
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical trials, Bleeding and Clotting, Hemophilia, Drug development, Clinical Research, Education, Supportive Care, Diseases, Therapy sequence, Gene Therapy, Real-world evidence, Treatment Considerations, Biological therapies, Adverse Events
Hematology Disease Topics & Pathways:
Research, Clinical trials, Bleeding and Clotting, Hemophilia, Drug development, Clinical Research, Education, Supportive Care, Diseases, Therapy sequence, Gene Therapy, Real-world evidence, Treatment Considerations, Biological therapies, Adverse Events
Friday, December 6, 2024: 11:00 AM-2:00 PM
Pacific Ballroom Salons 21-22
(Marriott Marquis San Diego Marina)
Chairs:
Stacy E. Croteau, MD, MMS, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
and
Guy Young, MD, Children's Hospital Los Angeles
Disclosures:
Croteau: BioMarin: Consultancy; Sanofi: Consultancy, Research Funding; Spark Therapeutics: Research Funding. Young: Genentech/Roche: Consultancy; CSL Behring: Consultancy; BioMarin: Consultancy, Speakers Bureau; Sanofi: Consultancy, Research Funding, Speakers Bureau; Hema Biologics: Consultancy, Speakers Bureau; Novo Nordisk: Consultancy; Pfizer: Consultancy; Takeda: Consultancy; Spark: Speakers Bureau; Roche: Consultancy.
Speakers:
Jennifer Maahs, RN, PNP, MSN, Indiana Hemophilia & Thrombosis Center
,
Jenny McDaniel, MD, Novant Health Hemby Children's Hospital
and
Cole Kruse, Lived Experience Expert
Disclosures:
McDaniel: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.
The session will focus on how new and emerging therapies for hemophilia will address the numerous unmet needs of patients, and will include expert presentations alongside panel-based discussions between two presenting faculty, who will be experts in hemophilia treatment, and three contributing faculty, who will be representatives of the HTC care team, including a community-based physician, a hemophilia nurse, and a patient with hemophilia. The content is designed to explore common questions, concerns, and insights from a variety of perspectives within the hemophilia community, allowing the new and emerging therapeutic landscape to be explored in a practice-relevant manner.
See more of: Friday Satellite Symposia